C
grade
Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling.
Thymodepressin · Molecular biomedicine · 2026 · Observational · Preclinical
Recombinant human Thymosin β4 showed potential in improving outcomes in experimental colitis models, but further research is needed to confirm its relevance in human IBD.
Not reported in abstract.